Compare NTHI & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTHI | JLS |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 100.6M |
| IPO Year | N/A | 2009 |
| Metric | NTHI | JLS |
|---|---|---|
| Price | $4.33 | $17.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 89.7K | 28.1K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $17.29 |
| 52 Week High | $12.99 | $19.09 |
| Indicator | NTHI | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 37.28 |
| Support Level | $4.17 | $17.41 |
| Resistance Level | $5.78 | $18.76 |
| Average True Range (ATR) | 0.48 | 0.23 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 7.88 | 21.83 |
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.